The drug, Zavzpret, was approved for the treatment of acute migraine, the company said. Zavzpret, to be launched in July, would be comparable in price to other FDA-approved migraine medicines that belong to the same class of drugs, Pfizer told Reuters. See here for a complete list of exchanges and delays